Use of Ruxolitinib to Resolve Ciltacabtagene Autoleucel–Induced Parkinsonism in Patients With Multiple Myeloma

Ruxolitinib has been identified as a potential effective treatment for parkinsonism arising from receipt of ciltacabtagene autoleucel in patients with multiple myeloma. A recently published case report detailed two patients with multiple myeloma who developed parkinsonism after receiving the CAR T-cell therapy, which was effectively controlled with ruxolitinib.